Nurix Therapeutics Q3 2026 Earnings: Revenue Hits $673.1 Million as Roche Deal Drives Profit

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up 8,426.3% YoY, driven by a Roche licensing deal. Net income was $549.8M, reversing a prior-year loss. Shares fell 2% in after-hours trading. The company has $1.1B in liquidity and a cash runway into 2H 2029. Revenue beat estimates, but much came from one-time license fees.

Original reporting
Published Oct 13, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nurix Therapeutics Q3 2026 Earnings: Revenue Hits $673.1 Million as Roche Deal Drives Profit — source image
Decision brief

The 30-second read

$NRIXBullishMed
01

Why it matters

The earnings release highlights a one‑time licensing cash infusion that boosts cash but also creates dependency on Roche, leading to mixed market reaction.

02

Market read

The report provides fresh earnings data for a mid‑cap biotech, with a notable licensing revenue spike that may affect valuation of similar partnership‑heavy firms.

03

What to watch

Roche cost‑sharing reduces R&D expense; the $27M milestone from Sanofi, Pfizer, Gilead may signal additional future collaborations.

Relevance 9/10Novelty 9/10Timing: after-hours today

Background

Nurix Therapeutics is a clinical‑stage biotech focused on targeted protein degradation, recently advancing its BTK degrader into Phase 3.

Company-level read

Ticker impact

$NRIXBullishHigh confidence
Context

Nurix Therapeutics reported Q3 2026 earnings with $673.1M revenue and $4.73 EPS, driven by a $700M Roche upfront payment, causing a 2% after‑hours share decline.

Expected impact

likely modest downside as market prices in the Roche licensing revenue and higher admin costs

Evidence & confidence

The earnings beat was offset by heavy reliance on a single licensing deal and a 2% post‑release price drop, suggesting short‑term pressure.

Market effects

Biotech licensing revenue models may be re‑valued; peers with similar collaboration structures could see comparable volatility.

U.S. biotech sector sees slight pullback as investors digest the earnings.

Limited to companies with large pharma partnership revenue streams.

Counterpoint

The Roche upfront payment provides a cash runway to 2029, potentially supporting a longer‑term upside despite short‑term sell‑off.

Key entities

  • Nurix Therapeutics

    NASDAQ‑listed biotech reporting Q3 2026 earnings.

  • Roche

    Pharma partner providing $700M upfront licensing payment.

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.